个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Etoposide induced NMI promotes cell apoptosis by activating the ARF-p53 signaling pathway in lung carcinoma.

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Dan Song[a] * ; Jiabao Zhao[b] * ; Chen Su[b,c] ; Ying Jiang[d] ; Jingjing Hou[a,b,c,*1] ;
机构： [a]State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen 361102, China [b]Institute of Gastrointestinal Oncology, Medical College of Xiamen University, Xiamen, Fujian 361004, China [c]Department of Gastrointestinal Surgery, Zhongshan Hospital of Xiamen University, Xiamen, Fujian 361004, China [d]West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
出处：
DOI： 10.1016/j.bbrc.2017.10.010
ISSN：

关键词： Etoposide NMI ARF Apoptosis

摘要：
Lung carcinoma is one of the leading causes of cancer-related death. The N-Myc and STATs interactor (NMI) has been reported to take participate in lots of physiological processes, but the involvement and functional mechanisms of NMI in lung carcinoma are poorly understood. In this study, we found that etoposide induces proliferation suppression, cell apoptosis and increases caspase-3 activity in A549 cells. Furthermore, etoposide treatment up-regulates the expression of NMI and ARF, enhances the interaction of NMI and ARF and promotes the p53 transcriptional activities. By contrast, when silencing NMI, the proliferation suppression and cell apoptosis caused by etoposide were repressed and the p53 signaling pathway activation was also suppressed. These investigations demonstrated etoposide-induced NMI can suppress tumor proliferation and promote cell apoptosis by activating the ARF-p53 signaling pathway in lung carcinoma. Our results provide an alternative mechanism for etoposide in lung carcinoma and suggest NMI has a critical role in suppressing lung carcinoma progression. Copyright © 2017 Elsevier Inc. All rights reserved.

基金：
This work was supported by grants from the National Natural Science Foundation of China (31501114) and the Foundation of Xiamen City (Grant No. 3502Z20174080).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2018]版：
大类 | 3 区 生物
小类 | 3 区 生物物理 4 区 生化与分子生物学
最新[2023]版：
大类 | 3 区 生物学
小类 | 3 区 生物物理 4 区 生化与分子生物学
第一作者：
第一作者机构： [a]State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen 361102, China
共同第一作者：
通讯作者：
通讯机构： [a]State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen 361102, China [b]Institute of Gastrointestinal Oncology, Medical College of Xiamen University, Xiamen, Fujian 361004, China [c]Department of Gastrointestinal Surgery, Zhongshan Hospital of Xiamen University, Xiamen, Fujian 361004, China [*1]Departmentof Gastrointestinal Surgery, Zhongshan Hospital of Xiamen University, 201-209, Hubin nan Road, Siming Area, Xiamen, Fujian 361004, China.
推荐引用方式(GB/T 7714)：
Dan Song,Jiabao Zhao,Chen Su,et al.Etoposide induced NMI promotes cell apoptosis by activating the ARF-p53 signaling pathway in lung carcinoma.[J].Biochemical and biophysical research communications.2018,495(1):368-374.doi:10.1016/j.bbrc.2017.10.010.
APA：
Dan Song,Jiabao Zhao,Chen Su,Ying Jiang&Jingjing Hou.(2018).Etoposide induced NMI promotes cell apoptosis by activating the ARF-p53 signaling pathway in lung carcinoma..Biochemical and biophysical research communications,495,(1)
MLA：
Dan Song,et al."Etoposide induced NMI promotes cell apoptosis by activating the ARF-p53 signaling pathway in lung carcinoma.".Biochemical and biophysical research communications 495..1(2018):368-374

相关文献

[1]PRL-3 promotes breast cancer progression by downregulating p14(ARF)-mediated p53 expression [2]Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas [3]NMI inhibits cancer stem cell traits by downregulating hTERT in breast cancer [4]顺铂及依托泊苷对神经母细胞瘤细胞中Trk基因家族表达的影响及临床意义 [5]Potentially functional variants of p14(ARF) are associated with HPV-positive oropharyngeal cancer patients and survival after definitive chemoradiotherapy [6]Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III study [7]Study of Platinum Plus Etoposide With or Without BGB-A317 in Participants With Untreated Extensive-Stage Small Cell Lung Cancer [8]Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer. [9]Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial [10]利妥昔单抗增敏navelbine诱导淋巴瘤细胞凋亡的实验研究

资源点击量：53105 今日访问量：0 总访问量：4588 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号